Total Remission of Severe Immune Thrombocytopenia after Short Term Treatment with Romiplostim

作者：Efthymia Vlachaki, Vaia Papageorgiou, Filippos Klonizakis, Maria Spandonidou, Sofia Chisan, Evaggelia Vetsiou, Elissavet Ioannidou · 发表于：Hematology Reports · 年份：2011 · 被引用次数：14 · 研究领域：Platelet Disorders and Treatments、Blood groups and transfusion、Autoimmune Bullous Skin Diseases

Immune thrombocytopenia (ITP) in adults is an acquired chronic immune-mediated disorder defined by isolated thrombocytopenia. In recent years, an improved understanding of the pathophysiology of ITP has been achieved and it is now accepted that the disorder is due to increased platelet destruction and decreased platelet production from megakary-ocytes. Thrombopoietin (TPO)-receptor agonists (romiplostim and eltrombopag) are new therapeutic modalities in the treatment of ITP. Here we describe a case of an elderly patient with severe ITP who presented complete remission after short-term use of romiplostim (only 3 weekly doses). This finding is quite interesting as the TPO-receptor agonists are, so far, believed to rarely lead to off-treatment sustained remission. The common notion of long-term use of romiplostim could be reexamined in future studies. Furthermore, the short term treatment with romiplostim may reduce the cost and the risk of side effects.